[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587808":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":42,"responsibleParty":113,"collaborators":115,"id":120,"slug":121,"hasResults":122,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":122,"sex":128,"minAge":129,"maxAge":26,"enrollmentInfo":130,"targetDuration":26,"studyType":133,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},{"fullName":5,"class":6},"University Hospital Ostrava","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Neoadjuvant NaSRT - prospective","EXPERIMENTAL","Patients undergoing neoadjuvant NaSRT will be enrolled prospectively in this study arm.",[13],"Radiation: Neoadjuvant Stereotactic Radiotherapy (NaSRT)",{"label":15,"type":16,"description":17,"interventionNames":18},"Postoperative SRT - retrospective","ACTIVE_COMPARATOR","Patients who underwent postoperative SRT in the past will be analyzed retrospectively in this study arm.",[19],"Radiation: Postoperative Stereotactic Radiotherapy (SRT)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","Neoadjuvant Stereotactic Radiotherapy (NaSRT)","Neoadjuvant Stereotactic Radiotherapy (NaSRT) gives radiotherapy before surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Postoperative Stereotactic Radiotherapy (SRT)","Postoperative Stereotactic Radiotherapy (SRT) gives radiotherapy after surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.",[15],[32],{"name":33,"affiliation":5,"role":34},"Jakub Cvek, Assoc.Prof., MD, Ing, PhD, MBA","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Jiří Hynčica","CONTACT","0042059737","2587","jiri.hyncica@fno.cz",[43,66,82,97],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":26,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Ostrava","Moravian-Silesian Region","70852","Czechia",{"type":50,"coordinates":51},"Point",[52,53],18.28204,49.83465,{"lat":53,"lon":52},[56,57,59,62,64],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},{"name":58,"role":34,"phone":26,"phoneExt":26,"email":26},"Jakub Cvek, Assoc.Prof.,MD, Ing., PhD, MBA",{"name":60,"role":61,"phone":26,"phoneExt":26,"email":26},"Štefan Reguli, MD, PhD","SUB_INVESTIGATOR",{"name":63,"role":61,"phone":26,"phoneExt":26,"email":26},"Jana Jackaninová, MD",{"name":65,"role":61,"phone":26,"phoneExt":26,"email":26},"Lukáš Knybel, Ing., PhD",{"facility":67,"status":44,"city":68,"state":26,"zip":69,"country":48,"countryCode":26,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Masaryk Memorial Cancer Institute","Brno","65653",{"type":50,"coordinates":71},[72,73],16.60796,49.19522,{"lat":73,"lon":72},[76,81],{"name":77,"role":38,"phone":78,"phoneExt":79,"email":80},"Tomáš Kazda, Assoc. Prof., MD, PhD","0042072544","0509","tomas.kazda@mou.cz",{"name":77,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":83,"status":44,"city":84,"state":26,"zip":85,"country":48,"countryCode":26,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"University Hospital Hradec Králové","Hradec Králové","50005",{"type":50,"coordinates":87},[88,89],15.83277,50.20923,{"lat":89,"lon":88},[92,96],{"name":93,"role":38,"phone":94,"phoneExt":26,"email":95},"Igor Sirák, Assoc. Prof., MD, PhD","00420608100251","igor.sirak@fnhk.cz",{"name":93,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":98,"status":44,"city":99,"state":26,"zip":100,"country":48,"countryCode":26,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"University Hospital Olomouc","Olomouc","77900",{"type":50,"coordinates":102},[103,104],17.25175,49.59552,{"lat":104,"lon":103},[107,112],{"name":108,"role":38,"phone":109,"phoneExt":110,"email":111},"Martin Doležel, prof., MD, PhD","0042073713","0111","dolezelm@email.cz",{"name":108,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":114,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[116,117,118],{"name":98,"class":6},{"name":67,"class":6},{"name":119,"class":6},"University Hospital Hradec Kralove","100587808","neoadjuvant-stereotactic-radiotherapy-for-brain-metastasis-100587808",false,"NCT06933199","Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis","Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis - Prospective Trial NeoSTROBE","NeoSTROBE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Karnofsky Performance Status ≥ 60\n* Histologically verified primary cancer disease\n* MRI findings indicating BM\n* Target BM indicated for surgical resection and any other metastases suitable for radical SRT.\n* Target BM between 1 cm and 7 cm at the longest diameter on T1 post-contrast MR imaging\n\nExclusion Criteria:\n\n* Confirmed hematological malignity\n* Small-cell (lung) carcinoma\n* Peracute condition requiring immediate neurosurgical intervention\n* History of whole-brain radiotherapy (WBRT)\n* History of stereotactic radiotherapy to a target brain metastasis\n* Pregnancy\n* Inability to perform surgical resection of the target BM within 7 days after NaSRT","ALL","18 Years",{"count":131,"type":132},260,"ESTIMATED","INTERVENTIONAL",[135],"NA","This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. The researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.",[138],"Brain Metastases",[138,140,141,142,143,144],"Neoadjuvant Stereotactic Radiotherapy","Leptomeningeal Disease","Quality of Life","Overall Survival","Acute Toxicity","2025-05-01",{"date":147,"type":148},"2025-05-04","ACTUAL",{"date":145,"type":132},{"date":151,"type":132},"2028-12-31",{"name":5,"class":6},4]